Saturday, November 23, 2024
HomeTagsCVXGA1

CVXGA1

CyanVac Announces Data from Preclinical Studies of Intranasal PIV5-based COVID-19 Vaccine Candidate CVXGA1

CyanVac LLC, a clinical-stage biopharmaceutical company developing intranasal vaccines using a proprietary transformational parainfluenza virus 5 (PIV5)-based vector, announced preclinical data in a hamster...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics